The Immunogen Production and Immunizations Core (Core B) will support activities in all three Projects of this HIVRAD application. Specifically many of the reagents and assays that support the activities of all three Projects have been consolidated in this Core. In addition, all animal-related activities have been consolidated in this Core. Studies in nonhuman primates (rhesus macaques) will be conducted in the Washington National Primate Research Center (WaNPRC). The WaNPRC will provide comprehensive, efficient and safe conduct of the nonhuman primate-related portions of the HIVRAD Program including animal selection, research protocol implementation and execution, sample acquisition and distribution, animal care, and project budget administration. Immunizations of rabbits and mice will be performed under a 'fee-for-service'agreement with Pocono Rabbit Farm and Laboratory Inc. Hybridoma generation will be performed at Viro Dynamics, under a 'fee-for-service'agreement. Sera and monoclonal antibodies from the immunized animals will be analyzed for specificity and neutralizing activity.
Identifying immunogens and immunization protocols for the optimal simulation of B cells to generate neutralizing antibodies against HIV, is crucial for the development of an effective vaccine against this virus. The studies in this proposal aim at providing key information on the intracellular events that follow the recognition of immunogens by B cells and which events lead to the production of protective anti-HIV antibody responses.
|Zhou, Tongqing; Doria-Rose, Nicole A; Cheng, Cheng et al. (2017) Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Rep 19:719-732|
|Jardine, Joseph G; Kulp, Daniel W; Havenar-Daughton, Colin et al. (2016) HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351:1458-63|
|McGuire, Andrew T; Gray, Matthew D; Dosenovic, Pia et al. (2016) Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun 7:10618|
|Strong, Roland K; Finton, Kathryn A K (2016) The Broadly Neutralizing, Anti-HIV Antibody 4E10: an Open and Shut Case? J Virol 90:3274-5|
|Tian, Ming; Cheng, Cheng; Chen, Xuejun et al. (2016) Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell 166:1471-1484.e18|
|Sok, Devin; Briney, Bryan; Jardine, Joseph G et al. (2016) Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 353:1557-1560|
|Dosenovic, Pia; von Boehmer, Lotta; Escolano, Amelia et al. (2015) Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell 161:1505-15|
|Jardine, Joseph G; Ota, Takayuki; Sok, Devin et al. (2015) HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349:156-61|
|Zhou, Tongqing; Lynch, Rebecca M; Chen, Lei et al. (2015) Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell 161:1280-92|
|McGuire, Andrew T; Glenn, Jolene A; Lippy, Adriana et al. (2014) Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol 88:2645-57|
Showing the most recent 10 out of 20 publications